Humulin R (Insulin Human (Rdna))

Humulin R is indicated for the control of hyperglycemia in patients with diabetes mellitus, providing rapid‑acting insulin coverage to mimic physiologic secretion after meals.

• Type 1 diabetes mellitus (insulin‑dependent)
• Type 2 diabetes mellitus (when diet, oral agents, or other insulins are insufficient)
• Management of diabetic ketoacidosis (IV administration)
• Peri‑operative glucose control in surgical patients
• Adjustment of basal‑bolus regimens for flexible dosing
• Use in pregnancy when benefits outweigh risks (if clinically indicated)
• Use in pediatric patients with type 1 diabetes under specialist supervision

• Humulin R contains recombinant human insulin that binds to insulin receptors on muscle, adipose, and hepatic cells. Receptor activation triggers autophosphorylation and downstream signaling through the PI3‑K/Akt pathway, promoting translocation of GLUT‑4 transporters to the cell membrane, increasing glucose uptake. In the liver, insulin suppresses gluconeogenesis and glycogenolysis, reducing endogenous glucose production. The rapid onset of action reflects its formulation, allowing prompt reduction of post‑prandial blood glucose.

Adverse reactions to Humulin R may occur; they are categorized by frequency and severity.

Common

• Mild hypoglycemia (sweating, tremor, hunger)
• Injection site reactions such as redness, swelling, or itching
• Lipodystrophy (localized fat loss or accumulation)
• Weight gain associated with improved glycemic control

Serious

• Severe hypoglycemia leading to loss of consciousness or seizures
• Allergic reactions including urticaria, angioedema, or anaphylaxis
• Hypersensitivity with eosinophilia or serum‑sickness‑like syndrome
• Persistent hyperglycemia due to insulin resistance or dosing errors

Before initiating Humulin R, clinicians should evaluate several safety considerations to minimize risk.

• Assess renal and hepatic function, as impairment may alter insulin clearance.
• Review history of hypoglycemia unawareness or previous severe episodes.
• Consider pregnancy, lactation, or planning for pregnancy; insulin may be required but risks should be discussed.
• Monitor for potential allergic reactions, especially in patients with known insulin or excipient sensitivities.
• Adjust dose during periods of illness, stress, or changes in physical activity.
• Use caution in elderly patients due to variable glucose tolerance.
• Ensure proper storage and handling to maintain product potency.

Humulin R can interact with other medicines; some combinations should be avoided while others require dose adjustments.

Avoid

• Concurrent use of other rapid‑acting insulins or insulin analogues without dose reduction, which may cause severe hypoglycemia.
• Beta‑blockers that mask hypoglycemia symptoms, increasing risk of unnoticed low glucose.
• High‑dose corticosteroids that markedly raise blood glucose, potentially overwhelming insulin effect.

Use with caution

• Oral antidiabetic agents (e.g., sulfonylureas, meglitinides) that also lower glucose; monitor for additive hypoglycemia.
• Diuretics that affect electrolyte balance and insulin sensitivity.
• ACE inhibitors or ARBs, which may enhance insulin sensitivity and alter glucose control.
• Alcohol consumption, which can cause delayed hypoglycemia; advise patient monitoring.